Tag: TSXV:IGX

January 15, 2020

IntelGenx Receives Authorization for Alzheimer’s Treatment Trial

Health Canada has issued a No Objection Letter in response to IntelGenx’s amended application for its ongoing trial in patients...
January 13, 2020

IntelGenx Confirms Cannabis-Infused Film Release in Q1 2020

IntelGenx confirmed that its cannabis-infused oral film, VersaFilm, is on track to be released commercially in Q1 2020.
October 9, 2019

IntelGenx Receives DSMB Recommendation for Phase 2a Trial

The Data Safety Monitoring Board completed its analysis of the company's Montelukast VersaFilm Phase 2a clinical trial of Alzheimer's Disease.
September 4, 2019

IntelGenx Partners with Tilray to Create Cannabis-infused Oral Strips

One pharmaceutical company is giving consumers the chance to experience the effects of cannabis in a new form: oral strips.
May 8, 2019

IntelGenx and Aquestive Therapeutics Enter Worldwide Collaboration Agreement for Tadalafil

IntelGenx (TSXV:IGX, OTCQX:IGXT) has announced it has entered into a partnership with Aquestive Therapeutics (NASDAQ:AQST) to co-develop and commercialize Tadalafil...
May 1, 2019

IntelGenx Shares Creation of New US Patent

IntelGenx announced the issuance of a patent from the United States Patent and Trademark Office covering the design and manufacturing of topical...
January 30, 2019

IntelGenx Facility Undergoes U.S. FDA Pre-Approval Inspection Related to RIZAPORT NDA

IntelGenx (TSXV:IGX,OTCQX:IGXT) a leading oral drug delivery company, today announced that the U.S. Food and Drug Administration has performed a...